Talphera (TLPH) Other Working Capital Changes (2010 - 2026)
Talphera (TLPH) posted Other Working Capital Changes of $683000.0 for Q2 2026, up 334.71% on a QoQ basis from -$291000.0 in Q1 2026, and up 371.03% year-over-year from $145000.0 in Q2 2025.
Analysis
Talphera (TLPH) Other Working Capital Changes (2010 - 2026) Analysis & Trends
Talphera has reported Other Working Capital Changes for 17 years, with the latest figure at $683000.0 in Q2 2026.
- On a quarterly basis, Other Working Capital Changes rose 371.03% year-over-year to $683000.0 in Q2 2026; TTM through Jun 2026 was $5000.0, a 100.45% increase from a year earlier, with the FY2025 full-year figure at -$35000.0, up 97.87% from the prior year.
- Other Working Capital Changes was $683000.0 for Q2 2026 at Talphera, up from -$291000.0 in the prior quarter.
- The five-year high for Other Working Capital Changes was $1.2 million in Q3 2021, with the low at -$2.8 million in Q2 2020.
- Average Other Working Capital Changes over 5 years is -$167214.3, with a median of -$46000.0 recorded in 2021.
- The largest YoY upside for Other Working Capital Changes was 1538.1% in 2023 against a maximum downside of 1744.44% in 2023.
- Over 5 years, Other Working Capital Changes stood at $76000.0 in 2022, then soared by 1402.63% to $1.1 million in 2023, then slumped by 145.88% to -$524000.0 in 2024, then jumped by 78.05% to -$115000.0 in 2025, then jumped by 693.91% to $683000.0 in 2026.
- The last three Other Working Capital Changes figures came in at $683000.0 (Q2 2026), -$291000.0 (Q1 2026), and -$115000.0 (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn |
| 10 | Talphera | 92.90 Mn | 92.90 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 683,000.00 |
| Jun 30, 2026 | 683,000.00 |
| Mar 31, 2026 | -291,000.00 |
| Mar 31, 2026 | -291,000.00 |
| Dec 31, 2025 | -115,000.00 |
| Dec 31, 2025 | -115,000.00 |
| Sep 30, 2025 | -272,000.00 |
| Sep 30, 2025 | -272,000.00 |
| Jun 30, 2025 | 145,000.00 |
| Jun 30, 2025 | 145,000.00 |
| Mar 31, 2025 | 207,000.00 |
| Mar 31, 2025 | 207,000.00 |
| Dec 31, 2024 | -524,000.00 |
| Dec 31, 2024 | -524,000.00 |
| Sep 30, 2024 | -936,000.00 |
| Sep 30, 2024 | -936,000.00 |
| Jun 30, 2024 | 645,000.00 |
| Jun 30, 2024 | 645,000.00 |
| Mar 31, 2024 | -826,000.00 |
| Mar 31, 2024 | -826,000.00 |